[The effect of several sexual steroids, 2-bromo-ergokryptin and lisurid-hydrogenmaleate an the postpartum concentration of serum prolactin and lactation (author's transl)]. 1977

M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel

The effect of Ablacton, Estrovis 4000, 2 Brom-alpha-ergokryptin (Cb 154) and of Lisurid-hydrogenmaleate (LHM) on lactation and the serum concentration of prolactin postpartum was studied. 10 normal nursing postpartum patients served as control. LHM was tested in a double blind study compared to placebo. The serum prolactin (PRL) was determined daily for the first 10 postpartum days by radioimmunoassay. Inhibition of lactation was consistent with Cb 154 (89% of the cases). Within two to three days after the onset of treatment with Cb 154 the changes of pregnancy in the breasts had completely subsided. The sexual steroids resulted in inhibition of lactation in 60% of the postpartum patients but mastodynia continued. LHM showed no difference from group taking placebo. The serum prolactin levels postpartum remained as high as a nursing mother's or rose with the administration of steroids. The administration of Cb 154 resulted in a drop of the serum prolactin to non-pregnant levels with in 2 days. The serum prolactin levels under treatment with LHM were not different from the group slowly. In nursing mothers, the stimulus of suckling maintain the pituitary secretion of prolactin as showed by higher serum prolactin levels and a slower decreased to normals than in the non-nursing mothers.

UI MeSH Term Description Entries
D007774 Lactation The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN. Lactation, Prolonged,Milk Secretion,Lactations, Prolonged,Milk Secretions,Prolonged Lactation,Prolonged Lactations
D009277 Nandrolone C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of ESTRADIOL to resemble TESTOSTERONE but less one carbon at the 19 position. 19-Nortestosterone,Estrenolone,Norandrostenolone,Nortestosterone,17-Hydroxy-Estr-4-Ene-3-One,17beta-Hydroxy-19-Nor-4-Androsten-3-One,17beta Hydroxy 19 Nor 4 Androsten 3 One
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D011800 Quinestrol The 3-cyclopentyl ether of ETHINYL ESTRADIOL. After gastrointestinal absorption, it is stored in ADIPOSE TISSUE, slowly released, and metabolized principally to the parent compound. It has been used in ESTROGEN REPLACEMENT THERAPY. (From AMA Drug Evaluations Annual, 1992, p1011) Ethinyl Estradiol 3-Cyclopentyl Ether,Estrovis,Ethinyl Estradiol 3 Cyclopentyl Ether
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen

Related Publications

M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
June 1979, Acta endocrinologica,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
January 1981, Zentralblatt fur Gynakologie,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
June 1977, MMW, Munchener medizinische Wochenschrift,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
January 1978, Nihon Jinzo Gakkai shi,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
October 1977, Wiener klinische Wochenschrift,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
November 1968, Experientia,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
December 1978, Journal de gynecologie, obstetrique et biologie de la reproduction,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
January 1976, L'Ateneo parmense. Acta bio-medica : organo della Societa di medicina e scienze naturali di Parma,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
March 1981, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
M Schmidt-Gollwitzer, and W Hardt, and K Schmidt-Gollwitzer, and E Michel, and J Nevinny-Stickel
January 1980, Annales d'endocrinologie,
Copied contents to your clipboard!